4 December 2020
Digital health expert Dr Jordan Brayanov from Takeda Pharmaceuticals shares his lessons learned delivering virtual trials during Covid-19 and predictions on what’s next for the industry.
16 November 2020
Using CANTAB to examine the potential synergistic effects of a combination of omega-3 fatty acids, carotenoids and vitamin E on the cognitive health and function of patients with MCI.
Dr Rebecca Power, Postdoctoral Researcher at the Nutrition Research Centre Ireland, shared the role that CANTAB played in her latest publication: Targeted Nutritional Intervention for Patients with Mild Cognitive Impairment: The Cognitive impAiRmEnt Study (CARES) Trial 1
5 November 2020
Industry experts working at the forefront of drug development, devices and digital health shared their lessons learned delivering virtual trials during the Covid-19 pandemic at Cambridge Cognition’s fourth annual Digital Health Event. Catch up on the key takeways from this thought-leading discussion.
4 November 2020
Automated administration of Serial Subtraction in a remote data collection context: novel timing features related to task difficulty and participant demographics
New research presented at CTAD 2020 reports the successful derivation of novel measures of timing for a more nuanced assessment of performance on the Serial Subtraction task.
20 October 2020
The volume of discussion and questions during our recent webinar: Remote Cognitive Testing and Lessons Learned During Lockdown was great to see. Unfortunately we were unable to answer all the questions in the time we had so Dr Caroline Skirrow has put together a Q and A addressing some of the key themes raised.
13 October 2020
CANTAB Research Grant assists research into defining cognitive phenotypes in individuals with CNVs associated with neurodevelopmental and neuropsychiatric disorders
Ciara Molloy recently spoke to us about the impact that receiving one of the three 2020 CANTAB Research Grant prizes will have on her research: ‘The impact of rare copy number variants on cognition: Defining cognitive phenotypes in individuals with CNVs associated with neurodevelopmental and neuropsychiatric disorders.’